What should I watch for in the generic price-fixing litigation?

The next major milestone is the first state trial, expected in Hartford, Connecticut in late 2026. That trial would put the states' evidence of industry-wide collusion before a jury for the first time and could influence remaining settlement talks, especially with Teva. The criminal phase is largely complete, although Teva's deferred prosecution agreement runs until its obligations, including a $135 million final payment in 2028, are met. Another question is whether courts accept the states' use of fraudulent transfer theories against parent companies, which the Sandoz settlement resolved without a ruling. And because many essential generics are made by only a handful of suppliers, the case has prompted wider debate about how to keep these markets competitive. With three state complaints outstanding, the first of which named Heritage and 17 other corporate defendants, the litigation is likely to continue for years.